Natural history of prostatism: risk factors for acute urinary retention.
about
5-alpha-reductase inhibitors for lower urinary tract symptoms secondary to benign prostatic obstructionThe role of alpha blockers prior to removal of urethral catheter for acute urinary retention in menAlpha blockers prior to removal of a catheter for acute urinary retention in adult menFinasteride in the treatment of clinical benign prostatic hyperplasia: a systematic review of randomised trials.Anatomy and Physiology of the Urinary Tract: Relation to Host Defense and Microbial InfectionFree prostate-specific antigen provides more precise data on benign prostate volume than total prostate-specific antigen in korean populationΑ₁-blockers in the management of acute urinary retention secondary to benign prostatic hyperplasia: a systematic review and meta-analysis.Dropout in a longitudinal, cohort study of urologic disease in community men.Acute urinary retention in men: an age old problem.Medical treatment of benign prostatic hyperplasia.Natural history of benign prostatic enlargement: long-term longitudinal population-based study of prostate volume doubling times.Smoking and acute urinary retention: the Olmsted County study of urinary symptoms and health status among men.Intravesical prostatic protrusion in men in Olmsted County, Minnesota.Acute urinary retention.Prevalence of erectile dysfunction in men over 40 years of age in Turkey: Results from the Turkish Society of Andrology Male Sexual Health Study GroupProstate volume measurement by transrectal ultrasonography: comparison of height obtained by use of transaxial and midsagittal scanning.Benign prostatic hyperplasia and male lower urinary tract symptoms (LUTS)Role of 5α-reductase inhibitors in benign prostatic diseases.Influence of intravesical prostatic protrusion on preoperative lower urinary tract symptoms and outcomes after 120 w high performance system laser treatment in men with benign prostatic hyperplasia.Estimation of prostate size in community-dwelling men.Prostate volume and prostate-specific antigen in the absence of prostate cancer: a review of the relationship and prediction of long-term outcomes.Efficacy and safety of dutasteride for the treatment of symptomatic benign prostatic hyperplasia (BPH): a systematic review and meta-analysis.Holmium laser enucleation (HoLEP) and photoselective vaporisation of the prostate (PVP) for patients with benign prostatic hyperplasia (BPH) and chronic urinary retention.Acute urinary retention: a review of the aetiology and management.Management of acute urinary retention: a worldwide survey of 6074 men with benign prostatic hyperplasiaLongitudinal changes of benign prostate-specific antigen and [-2]proprostate-specific antigen in seven years in a community-based sample of men.Benign prostate specific antigen distribution and associations with urological outcomes in community dwelling black and white men.Associations between variants in the cyclooxygenase 2 enzyme gene (PTGS2) and development of benign prostate enlargement.A Meta-Analysis of Long- Versus Short-Acting Phosphodiesterase 5 Inhibitors: Comparing Combination Use With α-Blockers and α-Blocker Monotherapy for Lower Urinary Tract Symptoms and Erectile Dysfunction.Preoperative Urinary Retention Increased the Risk of Urinary Retention after Photoselective Vaporization of the ProstateOutcomes and quality of life issues in the pharmacological management of benign prostatic hyperplasia (BPH)Identification of the patient with enlarged prostate: diagnosis and guidelines for management.Portable bladder ultrasound: an evidence-based analysis.Predictors of urgency improvement after Holmium laser enucleation of the prostate in men with benign prostatic hyperplasia.Mortality in men admitted to hospital with acute urinary retention: database analysis.Incidence of urinary retention during treatment with single tablet combinations of solifenacin+tamsulosin OCAS™ for up to 1 year in adult men with both storage and voiding LUTS: A subanalysis of the NEPTUNE/NEPTUNE II randomized controlled studies.Incidence and progression of lower urinary tract symptoms in a large prospective cohort of United States menBenign prostatic hyperplasia: an insight into current investigational medical therapies.Benign prostatic hyperplasia. Part 1--diagnosisAlfuzosin: an alpha1-receptor blocker for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia.
P2860
Q24188312-8D551931-0BE0-4CD4-9930-AE9FA3141F7AQ24194036-E5DCBD65-3565-4918-AF1B-0A301F4C04ECQ24240343-9804460D-9FD6-4C21-A1DF-E1E6FBB2CC1FQ24795452-FF0DCBEC-9664-4342-8672-32F03F783B64Q26782602-C3A7822E-AE91-4F71-8B8D-0F5337E09BC4Q30656133-FD7BA027-0929-4C43-B305-35B95C6913BCQ31153485-47906B82-C8AF-4B29-A20F-CD52AF3B2142Q33266615-F11D3AD9-9123-456C-92FE-54DC466A5CB8Q33548194-1F944311-73C6-4BFD-8C1D-0CBC99E01ABFQ33588534-61CDFB75-7B70-4753-980F-9FE768499D87Q33822350-1E1FC601-C359-4E3D-A521-C40844CE2393Q33822388-16E3BD2E-9AF3-4778-95C7-5CBBB1F20220Q33828154-225FF3DC-43AF-40BB-9D7F-1945FF03BE6AQ33836016-9AB31642-2522-4EC9-AC69-EABC64B02DEFQ33888517-0B1E64B8-5928-46DB-892E-6CDD27CBCF08Q33911754-8DFFBA59-45BB-497E-835B-3DC6B9A0BB3DQ34003918-5AFABC60-D28E-4A42-901E-4EC44311E27EQ34254296-096E7EB5-D1F4-4741-84D8-DACD9FFBCB85Q34367186-2CB774D8-DC9F-4F64-9F8D-07EF683147AAQ34441483-9334463E-C2D7-4E1D-AFDD-9857BC0E7210Q34464706-2566EC83-AA21-41EF-969E-87DABF3F473EQ35087049-44E36F74-37F8-4B84-9679-029B71DC7756Q35098042-055F2426-7449-4DE8-A38E-035A1833335EQ35681738-E7B1127A-4076-40C9-BC8E-7901ADDA59D1Q35737705-6CDA103A-96FB-42F0-BB53-3A074B9E3D33Q35816476-729B34CE-FAC7-45A2-8201-D9D7E64614EFQ35838386-E03BAD8A-DC25-4731-9DB6-73DF66C7BE55Q35860732-FFFED899-FB25-4718-AC7B-89ECC316F7F8Q35887478-053A02CB-FA80-4407-AE0A-3B7D3F18EB4DQ35894959-857EF7AA-CE1A-4B97-B935-D809DD23953DQ35919193-3193D455-F492-4094-9A90-1C3F7B5D1CD2Q35945368-E8ED9A49-DDBE-4C8F-B1E0-868666646B10Q36046936-2BEBF972-6AF5-4E4F-82C0-3BCCB51C97B0Q36193649-7876F28C-D35B-4ED1-9436-B1DA82823AEEQ36248512-D97187B7-DEE1-4FC3-A6C5-0D912E8189D3Q36271809-A2B7DB43-1956-4793-885F-EE5398D75E37Q36279542-5ACEE89E-9B8B-4826-A9DD-04599D832F9CQ36300022-FCC88796-DEDE-4230-83D1-CAA546A08357Q36392187-CA8B33C3-2AC9-4614-AA49-D411CB462CBDQ36428505-3FFECCAD-8301-44E4-A6B8-B86C431F1E4E
P2860
Natural history of prostatism: risk factors for acute urinary retention.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Natural history of prostatism: risk factors for acute urinary retention.
@en
type
label
Natural history of prostatism: risk factors for acute urinary retention.
@en
prefLabel
Natural history of prostatism: risk factors for acute urinary retention.
@en
P2093
P1476
Natural history of prostatism: risk factors for acute urinary retention.
@en
P2093
P304
P356
10.1016/S0022-5347(01)64508-7
P407
P577
1997-08-01T00:00:00Z